期刊文献+

儿童和青少年2型糖尿病的临床特点与治疗策略 被引量:6

Clinical features and treatment strategy of type 2 diabetes in children and adolescents
原文传递
导出
摘要 目前儿童和青少年的2型糖尿病发病率逐年增加,因此对其进行规范的诊断和治疗显得日益重要。儿童和青少年2型糖尿病的诊断包括糖尿病的诊断和其后的分型。糖尿病自身抗体检测,胰岛素和C肽释放试验均可帮助分型诊断,有时会出现分型困难的情况,这时要把重点放在有效控制血糖上。一旦确诊,必须马上开始改变生活方式,包括饮食、运动、控制体重等。药物治疗包括二甲双胍和胰岛素的单用或联用,治疗要根据高血糖的严重程度、有无酮症和(或)酮症酸中毒来选择。不同于1型糖尿病,2型糖尿病诊断伊始就要进行并发症和合并症的评估,同时在以后的随访中也要定期复查血脂、肝酶、尿白蛋白/肌酐比值,要监测血压,筛查阻塞性睡眠呼吸暂停(OSA)、糖尿病眼病等。 Type 2 diabetes in children and adolescents has be-come an increasingly important public health concern.The di-agnosis of type 2 diabetes requires confirmation of the pres-ence of diabetes, followed by determination of diabetes typeaccording to the diabetes autoantibody testing. Insulin and C-peptide release test is also helpful. Diagnosis of diabetes typein some patients can be confusing while emphasis should beput on the normalizing of blood glucose regardless of the ' type' of diabetes. Lifestyle change should be initiated at the timeof diagnosis of type 2 diabetes.Initial pharmacologic treatmentshould include metformin and insulin alone or in combination.The treatment is determined by symptoms, severity of hyper-glycemia, and presence or absence of ketosis/ketoacidosis.The presence of complications and comorbidities should be as-sessed at the time of diagnosis. Triglycerides, liver enzymesand urine albumin/creatinine ratio (ACR) should be obtained,and BP monitoring, and screening for obstructive sleep apnea(OSA) and diabetic retinopathy should also be done at thetime of diagnosis and during the follow-up.
作者 傅君芬
出处 《中国实用儿科杂志》 CSCD 北大核心 2015年第10期747-752,共6页 Chinese Journal of Practical Pediatrics
关键词 2型糖尿病 儿童和青少年 type 2 diabetes mellitus child and adolescent
  • 相关文献

参考文献13

  • 1Writing Group for the SEARCH for Diabetes in Youth Study Groupl, Dabelea D, Bell RA, et al. Incidence of diabetes in youth in the United States [J]. JAMA, 2007,297 (24) : 2716- 2724.
  • 2Ehtisham S, Hattersley AT, Dunger DB, et al. First UK survey of paediatric type 2 diabetes and MODY [J]. Arch Dis Child, 2004, 89(6): 526-529.
  • 3Weigensberg M J, Goran MI. Type 2 diabetes in children and ad- olescents[J]. Lancet, 2009, 373(9677) : 1743-1744.
  • 4Rosenbloom AL. Type 2 diabetes in children and adoles- cents[J]. Pediatr Diabetes,2009,10 (Suppl 12) : 17-32.
  • 5Zeitler P1, Fu J, Tandon N, et al.Type 2 diabetes in the child and adolescent[J]. Pediatr Diabetes, 2014,15 (Supp120) : 26-46.
  • 6Druet C, Tubiana-Rufi N, Cheyenne D, et al. Characterization of insulin secretion and resistance in type 2 diabetes of adoles- cents[J]. J Clin Endocrinol Metab, 2006, 91(2) : 401-404.
  • 7TODAY Study Group, Zeitler P, Hirst K, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes [J ]. N Engl J Med, 2012, 366(24): 2247-2256.
  • 8Kapadia CR. Are the ADA hemoglobin A (lc) criteria relevant for the diagnosis of type 2 diabetes in youth? [J]. Curr Diab Rep, 2013, 13(1): 51-55.
  • 9Umpaichitra V, Banerji MA, Castells S.Autoantibodies in chil- dren with type 2 diabetes mellitus [J]. J Pediatr Endocrinol Metab, 2002,15 (Suppl 1): 525-530.
  • 10Copeland KC, Zeitler P, Geffner M, et al.Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline [J]. J Clin Endocrinol Metab, 2011, 96(1): 159-167.

同被引文献84

  • 1中国1型糖尿病诊治指南:胰岛素治疗、医学营养治疗、运动治疗、其他治疗方法[J].中国医学前沿杂志(电子版),2013,5(11):48-56. 被引量:22
  • 2Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin : a novel secreted protein involved in the regulation of bone density [ J ]. Cell, 1997,89(2) :309-319. DOI:10. 1016/S0092-8674(00)80209-3.
  • 3Tsuda E, Goto M, Mochizuki S, et al. Isolationofa novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis [ J ]. Biochem B iophys Res Commun, 1997,234 ( 1 ) : 137-142. DOI: 10. 1006/bbrc. 1997. 6603.
  • 4Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor ( OCIF ) and osteoprotegerin ( OPG ) : a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro [ J ]. Endo- crinology, 1998, 139 ( 3 ) : 1329-1337. DOI: 10. 1210/endo. 139. 3. 5837.
  • 5. Baudhuin M, Duplomb L, Teletchea S, et al. Osteoprotegerin : multi- ple partners for multiple functions [ J ]. Cytokine Growth Factor Rev, 2013,24 (5) :401-409. DOI : 10. 1016/j. cytogfr. 2013.06. 001.
  • 6Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a recep- tor for the cytotoxic ligand TRAIL[ J]. J Biol Chem, 1998,273 ( 23 ) : 14363-14367. DOI : 10.1074/jbc. 273.23. 14363.
  • 7Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteopro- tegerin : paracrine regulators of bone metabolism and vascular function [ J]. Arterioscler Thromb Vasc Biol, 2002,22 ( 4 ) : 549-553. DOI: 10.1161/01. atv. 00(012303. 37971. da.
  • 8Anderson DM,Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and den- dritic-cell function [ J ]. Nature, 1997,390 ( 6656 ) : 175-179. DOI : 10. 1038/36593.
  • 9Wong BR, Josien R, Lee SY, et al. TRANCE ( tumor necrosis factor [ TNF]-related activation-induced cytokine ), a new TNF family member predominantly expressed in T cells,is a dendritic cell-specif- ic survival factor [ J ]. J Exp Med, 1997,186 ( 12 ) : 2075-2080. DOI : 10. 1084/jem. 186.12.2075.
  • 10Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cyto- kine that regulates osteoclast differentiation and activation [ J ]. Cell, 1998,93 ( 2 ) : 165 -176. DOI : 10.1016/s0092-8674 ( 00 ) 81569-x.

引证文献6

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部